|
AU2014203629A1
|
|
Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
|
|
AU2013211463A1
|
|
Pharmaceutical formulations
|
|
AU2013205602A1
|
|
Protein kinase c peptide modulators of angiogenesis
|
|
AU2012335009A1
|
|
Calcimimetics and methods for their use
|
|
WO2012170955A1
|
|
Therapeutic agents for regulating serum phosphorus
|
|
AU2010278897A1
|
|
Therapeutic agents for reducing parathyroid hormone levels
|
|
CN101820756A
|
|
Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
|
|
CN101969960A
|
|
Methods of use of gamma inhibitor compounds for the attenuation of pain
|
|
WO2008089494A2
|
|
Methods of use of epsilon inhibitor compounds for the attenuation of pain
|
|
CN108948144A
|
|
The modification of peptide combinations is to improve stability and delivery efficiency
|
|
CN101668421A
|
|
Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
|
|
EP2194124A1
|
|
Protein kinase c peptide modulators of angiogenesis
|
|
US2006153867A1
|
|
Pharmaceutical formulation
|
